300267.SZ
Hunan Er-Kang Pharmaceutical Co., Ltd.
SZSE · Healthcare · C 制造业 · CN
CNY 2.82
+1.81%Year over year
Reported trailing growth
- Revenue
- -13.0%
- EBITDA
- —
- EBIT
- -10.4%
- EPS
- -13.4%
- Free cash flow
- +481.1%
- Operating cash flow
- +65.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -14.6%
- EBITDA
- -6.5%
- EBIT
- +1.5%
- Net income
- -1.7%
- EPS
- -1.7%
- Free cash flow
- -4.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026